前列地尔联合厄贝沙坦治疗糖尿病肾病的效果观察被引量：3

导出

摘要目的观察前列地尔联合血管紧张素Ⅱ受体阻滞剂厄贝沙坦对糖尿病肾病患者的疗效。方法 94例糖尿病肾病患者随机分为对照组和观察组,每组47例,对照组单用厄贝沙坦治疗,观察组同时给予前列地尔及厄贝沙坦治疗,对比两组的疗效。结果两组治疗后的血肌酐(Scr)、肌酐清除率(Ccr)、尿素氮(BUN)及尿白蛋白排泄率(UAER)均有明显改善(P<0.05或0.01);观察组各指标改善更为明显(P<0.05或0.01)。结论前列地尔和厄贝沙坦联合应用对糖尿病肾病的肾脏保护具有叠加作用。

作者林少斌陈文炯

机构地区广东省普宁市人民医院

出处《广东医学院学报》 2014年第3期383-384,共2页 Journal of Guangdong Medical College

关键词糖尿病肾病前列地尔血管紧张素Ⅱ受体阻滞剂厄贝沙坦

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献11

1李阳.糖尿病肾病的发病机制及治疗进展[J].当代医学,2010,16(26):18-20. 被引量：40
2Evans M, Bain S C, Hogan S, et al. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate:post hoc analysis of the Irbesartan Diabetic Nephropathy Trial[J]. Nephrol Dial Transplant, 2012, 27(6):2255-2263.
3佟晶洁,刘小燕,傅增泮.前列地尔对糖尿病肾病患者血液流变学及尿白蛋白作用的观察[J].中华实用诊断与治疗杂志,2008,22(8):592-594. 被引量：20
4Mogenson C E, Chrietenzen C K. The diabetic Kidney from hyper- filtration and microalbumin to end-stage renal failure[J]. Med Clin Nor Am, 1988, 72 (6):1465- 1467.
5陈素霞.前列地尔注射液联合厄贝沙坦治疗糖尿病肾病的疗效[J].中国医药指南,2012,10(6):120-121. 被引量：3
6刘焕兵,熊晶,潘思生.缬沙坦治疗老年早期糖尿病肾病的疗效观察[J].实用临床医学（江西）,2008,9(4):41-41. 被引量：3
7秦卫国,陈海燕.疏血通注射液与贝那普利联合治疗早期糖尿病肾病40例疗效观察[J].广东医学院学报,2010,28(1):29-30. 被引量：6
8林佃新,刘印,巩立营.前列腺素E1脂微球制剂联合厄贝沙坦治疗早期糖尿病肾病的疗效观察[J].安徽医药,2008,12(9):860-861. 被引量：12
9Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection:a lesson from clinical trials[J]. Curt Pharm Des, 2007, 13(13):1335-1345.
10刘绍田.早期糖尿病肾病临床疗效观察[J].中国医药指南,2010,8(13):77-78. 被引量：8

二级参考文献36

1邹继红,寿伟璋,阎福岭,谢玉兰,王建伟.前列地尔对糖尿病肾病尿清蛋白排泄率、血小板活化和血脂的影响[J].中国新药与临床杂志,2004,23(7):409-411. 被引量：24
2周希静.糖尿病肾病的早期诊断与鉴别诊断[J].实用内科杂志,1993,13(5):262-263. 被引量：25
3李佑生,王文健.中医药防治糖尿病肾病的机制研究述评[J].上海中医药杂志,2005,39(10):56-59. 被引量：20
4Mogensen C E,Schmitz A,Christensen C K.Comparative renal pathophysiology relevant to IDDM and NIDDM patients[J].Diabetes Metabol Rev,1998,4(5):453-483.
5[2]Jerums G,Auen TJ,Canmpell DJ,et al.Long-term comparison between perimdopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminutia.Am J Kidney Dis,2001,37 (5):890-899.
6Ceriello A.New insights on oxidative stress and diabetic complications may lead to"causal"antioxidant therapy[J].Diabetes Care,2003,26(5):1589-1596.
7Body-White J,Williams JC.Effect of cross-linking on matrixperme ability:a model for AGE2 modified basementmembranes[J].Kidney Int,1996,46(3):348-353.
8Karamanos B,Porta M,Songini M,et al.Different risk factors of microangiopathy in patients with type 1 diabetes mellitus of shorter long duration:the Eurodiab IDDM Comp lications Study[J].Diabetologia,2000,43(3):348-355.
9Barroso LC,Herrera ND,Hueros JC.et al.lncidence of cardiovascular disease and vajidity of equations of coronary risk in diabeticpatients with metabolic syndrome[J].Med Clin(Barc),2007,128(14):529-535.
10No authors listed.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKFDS 391UK Prospective Diabetes Study Group[J],BMJ,1998,317(7160):713-720.